Patient Characteristics
| Pt. No. . | UPN . | Age . | Sex . | Stage at Dx . | Months From dx to BMT . | Stage at BMT . | Donor-Sex . | Cond. Regimen . | GVHD Prophylaxis . | GVHD After BMT . | Mos BMT to Relapse . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3853 | 52 | M | CP | 1 | CP | syn-M | Cy/TBI | None | NA | 12 |
| 2 | 4329 | 34 | F | CP | 11 | CP | allo-M | Cy/TBI | MTX/CSP | 0 | 27 |
| 3 | 4161 | 39 | M | CP | 2 | CP | syn-M | Cy/TBI | None | NA | 12 |
| 4 | 4399 | 33 | F | CP | 11 | CP | allo-F | Cy/TBI | MTX/CSP | 0 | 26 |
| 6 | 3375 | 27 | M | CP | 3 | CP | allo-M | Cy/TBI | MTX/CSP | 0 | 57 |
| 7 | 4226 | 28 | F | CP | 11 | CP | allo-M | Cy/TBI | MTX/CSP | a-s, g | 41 |
| 9 | 5256 | 58 | M | CP | 16 | CP | allo-F | Cy/TBI | MTX/CSP | 0 | 28 |
| 11 | 6595 | 12 | F | CP | 3 | CP | allo-M | Bu/Cy | MTX/CSP | 0 | 1 |
| 12 | 4642 | 29 | F | CP | 9 | CP | allo-M | Cy/TBI | MTX/CSP | a-s | 34 |
| 13 | 6567 | 48 | M | CP | 7 | CP | allo-M | Cy/TBI | MTX/CSP | a-g, c-m | 2 |
| 14 | 7035 | 20 | M | CP | 4 | CP | allo-M | Cy/TBI | MTX/CSP | a-g | 2.5 |
| 15 | 6404 | 51 | F | CP | 119 | CP | allo-M | Cy/TBI | MTX/CSP | a-l, g | 19 |
| 16 | 7400 | 32 | M | CP | 5 | CP | allo-M | Cy/TBI | MTX/CSP | c-m | 11 |
| 17 | 6603 | 61 | M | CP | 8 | CP | allo-M | Bu/Cy | MTX/CSP | a-g | 3 |
| Pt. No. . | UPN . | Age . | Sex . | Stage at Dx . | Months From dx to BMT . | Stage at BMT . | Donor-Sex . | Cond. Regimen . | GVHD Prophylaxis . | GVHD After BMT . | Mos BMT to Relapse . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3853 | 52 | M | CP | 1 | CP | syn-M | Cy/TBI | None | NA | 12 |
| 2 | 4329 | 34 | F | CP | 11 | CP | allo-M | Cy/TBI | MTX/CSP | 0 | 27 |
| 3 | 4161 | 39 | M | CP | 2 | CP | syn-M | Cy/TBI | None | NA | 12 |
| 4 | 4399 | 33 | F | CP | 11 | CP | allo-F | Cy/TBI | MTX/CSP | 0 | 26 |
| 6 | 3375 | 27 | M | CP | 3 | CP | allo-M | Cy/TBI | MTX/CSP | 0 | 57 |
| 7 | 4226 | 28 | F | CP | 11 | CP | allo-M | Cy/TBI | MTX/CSP | a-s, g | 41 |
| 9 | 5256 | 58 | M | CP | 16 | CP | allo-F | Cy/TBI | MTX/CSP | 0 | 28 |
| 11 | 6595 | 12 | F | CP | 3 | CP | allo-M | Bu/Cy | MTX/CSP | 0 | 1 |
| 12 | 4642 | 29 | F | CP | 9 | CP | allo-M | Cy/TBI | MTX/CSP | a-s | 34 |
| 13 | 6567 | 48 | M | CP | 7 | CP | allo-M | Cy/TBI | MTX/CSP | a-g, c-m | 2 |
| 14 | 7035 | 20 | M | CP | 4 | CP | allo-M | Cy/TBI | MTX/CSP | a-g | 2.5 |
| 15 | 6404 | 51 | F | CP | 119 | CP | allo-M | Cy/TBI | MTX/CSP | a-l, g | 19 |
| 16 | 7400 | 32 | M | CP | 5 | CP | allo-M | Cy/TBI | MTX/CSP | c-m | 11 |
| 17 | 6603 | 61 | M | CP | 8 | CP | allo-M | Bu/Cy | MTX/CSP | a-g | 3 |
Abbreviations: Pt. No., patient number; UPN, Unique Patient Number; dx, diagnosis; mos, months; BMT, bone marrow transplant; Cond, conditioning; GVHD, graft-versus-host disease; IFN, interferon; CP, chronic phase; syn, syngeneic; allo, allogeneic; MTX, methotrexate; CSP, cyclosporine; TBI, total body irradiation; Bu, busulfan; NA, not applicable; a, acute; s, skin; g, gastrointestinal; c, chronic; m, mucosal; l, liver.